Cargando…
Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints
Autores principales: | Petersen, Ronald C., Graf, Ana, Carrillo, Maria C., Weber, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583953/ https://www.ncbi.nlm.nih.gov/pubmed/36284665 http://dx.doi.org/10.1002/trc2.12361 |
Ejemplares similares
-
Understanding the Pathophysiology of Cerebral Amyloid Angiopathy
por: Gatti, Laura, et al.
Publicado: (2020) -
Physiological Roles of β-amyloid in Regulating Synaptic Function: Implications for AD Pathophysiology
por: Cai, Wenwen, et al.
Publicado: (2022) -
Dentists added to PPE portal
Publicado: (2020) -
Understanding the Use of Composite Endpoints in Clinical Trials
por: McCoy, C. Eric
Publicado: (2018) -
Imaging β amyloid's pore performance
por: Short, Ben
Publicado: (2011)